Get the Stockscreener App
28.00
21.21%
4.90
Tonix Pharmaceuticals Holding Corp stock is traded at $28.00, with a volume of 2.51M.
It is up +21.21% in the last 24 hours and up +76.54% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$23.10
Open:
$25.17
24h Volume:
2.51M
Relative Volume:
2.01
Market Cap:
$205.24M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-2.4867
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
+48.70%
1M Performance:
+76.54%
6M Performance:
+113.58%
1Y Performance:
-95.18%
1-Day Range:
$25.00
$30.20
1-Week Range:
$18.50
$30.20
52-Week Range:
$7.31
$672.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
28.00 | 129.51M | 0 | -121.02M | -114.09M | -11.26 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results - Benzinga
Stocks To Watch: Tonix Pharmaceuticals Sees RS Rating Jump To 89 - inkl
Tonix Pharmaceuticals Recruits Seasoned Industry Atty As GC - Law360
Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - Investing.com India
Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - citybiz
Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EV - GuruFocus
Tonix Pharma Appoints New General Counsel and EVP - TipRanks
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, - GlobeNewswire
Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Tonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats - GuruFocus
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Tonix Pharma earnings beat by $22.84, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewswire
Tonix Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals reports annual meeting results - Investing.com Australia
Tonix showcases promising gastric cancer data at AACR Conference - Proactive financial news
(TNXP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity - Seeking Alpha
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -
Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks
Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire
Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting - The Manila Times
Tonix Pharmaceuticals and Makana partner to advance research with Anti-Rejection therapy - Proactive Investors
Groundbreaking Cancer Therapy Shows Promise: Tonix's New Combination Treatment Activates Cancer-Killing Cells - Stock Titan
Tonix culls cocaine intoxication trial amid enrollment woes - Fierce Biotech
Tonix Pharmaceuticals Holding CorpDiscontinued Enrollment And Terminated Phase 2 Catalyst StudySEC Filing - marketscreener.com
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data - citybuzz -
Tonix reports promising results for mpox vaccine TNX-801 By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Unveils Promising Results for Single-Dose Mpox Vaccine | TNXP Stock News - GuruFocus
Tonix reports promising results for mpox vaccine TNX-801 - Investing.com
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine T - GuruFocus
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - The Manila Times
Tonix Pharmaceuticals Presented Data on Potential Mpox - GlobeNewswire
Tonix Pharma Presents Promising Vaccine Data at Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Falls Despite Market Upturn - GuruFocus
Tonix Pharmaceuticals (TNXP) to Present at World Vaccine Congres - GuruFocus
When the Price of (TNXP) Talks, People Listen - news.stocktradersdaily.com
Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025 - marketscreener.com
Tonix Pharmaceuticals Announces Oral Presentation and Panel - GlobeNewswire
Major Breakthrough: Tonix Unveils Single-Dose Mpox Vaccine Data at Leading Global Conference - Stock Titan
Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? - MSN
Tonix and Makana partner on xenotransplantation research By Investing.com - Investing.com India
Tonix Pharmaceuticals and Makana Therapeutics Announce Collabora - GuruFocus
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):